Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBIT (2016 - 2025)

Historic EBIT for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$2.0 million.

  • Aytu Biopharma's EBIT fell 1622.42% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.7 million, marking a year-over-year decrease of 2249.05%. This contributed to the annual value of -$7.8 million for FY2025, which is 25920.15% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's EBIT is -$2.0 million, which was down 1622.42% from -$1.5 million recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's EBIT peaked at $3.1 million during Q4 2023, and registered a low of -$53.4 million during Q1 2022.
  • Over the past 5 years, Aytu Biopharma's median EBIT value was -$2.4 million (recorded in 2024), while the average stood at -$9.5 million.
  • In the last 5 years, Aytu Biopharma's EBIT plummeted by 179289.94% in 2024 and then soared by 25159.67% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's EBIT stood at -$11.3 million in 2021, then soared by 39.19% to -$6.9 million in 2022, then soared by 145.81% to $3.1 million in 2023, then tumbled by 153.88% to -$1.7 million in 2024, then fell by 16.22% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q4 2025, -$1.5 million for Q3 2025, and -$7.6 million during Q2 2025.